Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug

Core Viewpoint - The FDA has determined that there is insufficient evidence of effectiveness for relacorilant in treating patients with Cushing syndrome and hypertension, resulting in a significant decline in the stock price [1] Group 1 - The FDA's decision highlights concerns regarding the efficacy of relacorilant, which may impact its market potential and investor confidence [1] - The announcement has led to a sharp decrease in the stock value, indicating a negative market reaction to the FDA's findings [1]